Silk Therapeutics develops clean, EWG VERIFIED skincare collections built around pure, liquid silk as the core active ingredient. After receiving five patent approvals in 2016, the company built a natural chemistry platform to produce liquid silk at mass scale. Leadership under CEO Greg Altman and COO Rebecca Lacouture has extended the technology beyond skincare: testing revealed use cases in fabrics where liquid silk infused into the surface layer offers benefits for performance apparel. The company is focused on expanding its development efforts and commercial applications of the liquid silk platform. Financially, Silk Therapeutics recently closed an $11M Series A3 financing to support those development plans. Silk Therapeutics is a Boston, MA–based company that provides silk protein solutions for human health and wellness. The company has patented natural silk protein technology for use in consumer goods and medical applications and offers a skincare product line designed to renew, fortify and nurture the skin. Led by CEO Dr. Greg Altman and COO Dr. Rebecca Horan, Silk will use the new capital to expand its skincare product line and begin exploring additional consumer markets. The company closed a $6M Series A2 financing round to support those efforts. The round was led by existing investor The Kraft Group and included participation from Lear Corporation, Highland Consumer Partners, Sheri and Roy P. Disney, Richard Sackler, MD (with Summer Road, LLC), Erin Donohue and Ron Bresler (BML Group), and Altman Health Investments. With this A2, Silk has now raised a total of $10.25M in Series A funding. Silk Therapeutics develops silk protein–based solutions focused on skin health and wellness. The company is preparing to launch a sensitive skincare treatment line in the second half of the year aimed at people with sensitive skin, eczema, and oncology patients undergoing chemotherapy and radiation. Products are designed to heal, soothe and restore damaged and inflamed skin. Leadership includes Gregory Altman, PhD (CEO and co‑Founder), and Rebecca Horan, PhD (COO). Silk Therapeutics recently closed a $3M Series A1 financing to support its product plans and operations. The company is based in Boston, MA.

Total raised

$20M

Funding rounds

3

Latest round

Series A

Latest activity

Sep 2017